LUNG CANCER RESEARCH (CHARITY COMMISSION NO. 1101823) ACCOUNTS 31 DECEMBER 2024
LUNG CANCER RESEARCH ICHARrrY COMMISSION NO. 11018231 ACCOUNTS FOR THE YEAR ENDED 31 DECEMBER 2024 CONTENTS PAGE Trustees. Report A0tants, Report Independent Examiners Report Balance Sheet statement of Financial Activrties Notes to the Accounts 10
LUNG CANCER RESEARCH (CHARITY COMMISSION NO. 11018231 TRUSTEES. REPORT FOR THE YEAR ENDED 31 DECEMBER 2024 Registered Charity Numb•r 1101823 Prln¢lFial Addre8¥ clo ston Reeves LLP, 168 Shoreditch Hyh Street, 2rxl Fk>or, LoNlon, E16RA Governing Document Settrnent Deed dated 20th January 2004 Htsw Constitutod As a trust Objects of the Charity The assets a held on trust to fund dinical labDf8lory and epiderniological researd) Into the causes, prevention and tatment of Lung Cancer. In setting our objectives and planning our activitte5 thé Trustees have given careful consideration to the Charity Cornmi88ion'3 g8ner81 guidance on publi¢ l)enÈlrt. Aecountsnts Kreston Reeves LLP 2nd Floor. 168 Shoreditch High Street London E16RA Bankèrs HSBC Bank pfc 12 Hampslea¢ HwJh Street Hampstead London NW31PY Trustees Robin Ellison Ifftld 17th February 20251 Alastair Meeks Michael Seckl Nicci WyboTII Trust•• Stlèction Appointsnent by existing trustees MISSION STATEMENT Introduction Lung Cancer Research was e8tabli8hed 8$ 8 r8gistered charity in 2004 to support the researd) the fiekl tsf lufig canr. Lung canr is poorly supported by the rnainstrBam cancer chanties. partly because rt 1$ seen a$ 8 881f- inflicted disease in many e2ses. There ale fourtrusteos of the charity.. Robin Ellison (retired 17th February 20251 Mr Alastair Meeks Professor Michael Se¢1 M5 Nicu Wyborn Professor Ellison and Alastair Meeks are experience(I trust 5avryers. Professor Sed(l is a woradIng researcher in the f1 of lung ¢anr£r. Ms Wybom is a lun9 can¢r surwivor.
LUNG CANCER RESEARCH ICHARITY COMMISSION NO. 11018231 TRUSTEES, REPORT FOR THE YEAR ENDED 31 DECEMBER 2024 Alastair Meeks Alastsir Meeks is a tired solicitor. Until May 2020 he wa5 a partner in Ptnsent Masons and practi5ed p&n8n$ law. He ¥Kd8 thair of the Association of PeTh¥ign Lawyers frorn 2007 to 2009 and is a F811ow of the P8nsion8 Management Institutg. He acted in relation to many landmark pension (ases. in¢luding the ITN case and BESTfUStees v Stuart, both of which explored the interaction between explanatory literature and trust documentation. He 8Cted for the trustees of Anglo United Pension Scheme and the Dexion Scheme, 8nd in the process helped prompt the establk8hmen¢ ofthe DWP'S Financial AssBtsnce Scheme. He is the author of To11ey's Pensions Cases, the definitive wosl( on the subject currentty edits the pensions cases section of To1Y'S Pensions Law. He now taking up a rok as a professional trustee with Zedra as from October 2023. Profvssor Seekl Michael Seckl. MD. PhD. Fmedsu trained medicine and science at University College London Iunited Kingdom) obtaining a BSC in immunology in 1983 and his MBBS in 1986. He did his general professional and special1 rnedical oncology training on the London circulL, and became a fellow ol the Royal College of Physician5. He obtained his PhD biochernistry in 1995 frotn the London Research Institute (now known as the CRICKyUnivers¥ty College London and wa8 that year appointed a8 a senior lecturerlhonorary consuttant in medical oncology at Charing Cross Hospital in London, now part of Imperial College London. He then establishèd his own research groups working on cel signalling in lung eanor and trophoblastic cancers 5UPPOrted by grants from Cancer Research UK, th8 Medul Re588rch Council, Wellcome Trust, Wellbeing. industry, and others. He was promoted to reader in 2002 and profes50r ol rnolecular oncology in 2004, wen he 8190 took on the directorship of the Charing Cross Gestational Trophoblastic Disease Centre and the suprareglonal Tumour MarkerAssay Serv1. Professor Seckl also leads the Imperial COlle Experimental Canr Medicine Centre, the Imperial Canr Trials unit. njns the London Lung canrAIli8n and has run multiple Phase 1-111 trials. He is on the e(litorial board of several journals and ¢hairslsits on several grants committees. He is the immediate past-president of the Royal Soaety of MediciTr¢ Oncology sedion and European Organksation for the TreatMt of TTophoblstic Disease. He was also past president and Is the current treaSUr of the Internation81 Society for the Study of Trophobla3lic Disease and hold3 an honorary professorshtp with thg Peking Union Medical College in China. He also established and now ¢0-ad$ the gynae¢ologiGal caThr domain within the European Rare Adult Cancel Nelwork IEURACANI. Educationally, he was director of postgraduate studEs for the Departsrent of Surgery Cancèr with overall responsibility for 200 MSclMRes and 400 PhD students between 2012- 2022. Within his own research group. he and his team have reiVed numerous national and international awards and in the past 5 years have raised over 218M of grant income. He has published over 280 peer reviewed manuscripts many appearin9 in adIng scEnts"lic and medical journals such as Lant, Laneet Oncotogy, New England J ol MediciTre, Nature comrnunications, scien Translational Medicine and J Clinical Oncology. In recognition for hB contributions to medical SCnCe and his international leadetship he was made a Felbw of the Academy of Medical Scien$ in 2017. He remains committed to teaching. rese8h. and his patients.
LUNG CANCER RESEARCH ICHARITY COMMISSION NO. 11018231 TRUSTEES. REPORT FOR THE YEAR ENDED 31 DECEMBER 2024 Nl¢¢l Wyborn Nicci is a Senior Pensions Consultsnt In the Pinsent Mastsns Pensions Solutions business at Pinsent Masons. In her current role she speualises in risk, governance and project management services for clients th both defined benefit IDBI and defined contribution IDCI pension schemes, working c105ely wth trustee boards, P&n5ions Managers and HR Directors. Clients include a £5.5 billion pension $¢heme IDBIDCI, a £1 billion pension scheme IDBlwith AVCS), 3 £700 million pension scheme lopen DBI and £300 rnillion pension scheme IDBIDCI. Nicci had been at Pin5ent Masons for nearly 23 years starting her C&er 8$ a PA in the pensions group. before moving to Pinsent Masons Penston8 Soluhons in 2017. NieLi had lung surgery in 2018 for a ¢arcinoid lung tumour so the work funded by the charity 18 extr8m81y important to her. I dedare that in my r2parity of charity trustee, that". - the Trustees havo approved the report above.. and - have authorised me sign it on their behalf. Alastair Meeks Trustee
LUNG CANCER RESEARCH (CHARITY COMMISSION NO. 1101823} ACCOUNTANTS. REPORT FOR THE YEAR ENDED 31 DECEMBER 2024 In accordance wrth the engagement letter of 3 September 2013 we have prepared the accounts, sel out on pages 8 10 10, from the accounting records of the Trustees and infomiation and explanations given to us. These accounts have been compiled in aceordance wf(h the accounting policies sel out in Note 110 these aecounls. These accounts are not intended lo comply fully w(ch the provisions of'UK Generally Accepted A¢¢ounting Principles.. This report is made to the Trustees of Lung Cancer Research TNst, in aeeordance with the terms of our engagement. Our work has been undertaken so that we might prepare the accounts, report that we have done so and stae those matters which we feel should be drawn lo the Trustees, attention and for no oth&r purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to arsyone, other than the Trustees, for our work or for this report. We have carried out this engagement in accordance wilh technical guidelines issued by the Institute of Chartered Accountsnts in England & Wales and by th& Society of Trust and Estate Pracli(ioners. We have compiled this report with ethical guidance laKI down by those bodies. We have not been instructed to carry out an audit of these accourbts. For this reason, we have not verified the ac¢uTacy or completeness of the accounting records or information and explanations given to us and we do not, therefore, expr8ss any opinion on these accounts. Il,,k Lgs LL Kreston Reeves LLP Chartered Accountants 2nd FEoor 168 Shoredrtch High Street London EI 6RA ACCOUNTS APPROVAL CERTIFICATE We approve these accounts and confimi that we have made available all relevant records and information for their pparatIOrt. Robin Ellison Alastair Meek Jkny Michael Seckl Nicci Wborn
LUNG CANCER RESEARCH ICHARITY COMMISSION NO. 11018231 INDEPENDENT EXAMINER'S REPORT FOR THE YEAR ENDED 31 DECEMBER 2024 I report on the accounts for the year ended 31st DeceTMber 2024 which are sel out on pages 8 to 10. Res ective Res onsibilities of Trustees and Examiner The charity's trustees are responsible for the preparation of the accounts. The charity's trustees consider that an audit is not required for this year under section 144 of the Charities Act 2011 I'lhe Charities Act l and that an independent examination is needed. It is my sponsibl11tY to.. examine the accounts under section 145 of the Charities Act, lo follow the procedures laid down in the general Directions given by the Charity Commission lunder section 14515llbl of the Charilies Act, and to state whether parti¢ular matters have ¢ome to my attention. Basis of Examinerfs Re ort My examination was carried out in accordance with general Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charity and 8 ¢omp8rison of the accounts presented with those records.11 also includes consideration of any unusual items or disclosures in the accounts. and seeking explanations from the trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit, and consequenlly no opinion is given as to whether the accounts present a 'true and fair, view and the report is limited to those matters set OLJt in the statement below. Ind¢ èndènt Examln¢r'$ Re ort In connection with my examination, no matter has come to my attention:_ Which gives me reasonable cause to believe that in any material respect the requirements to keep accounting records in accordance with Section 130 of the Charities Act,. and to prepare accounis which accord with the accounting records and to comply with the accounting requirements of the Charities Act have not been met., or to which, in my opinion, attention should be drawn in order lo enable a proper understanding of the accounts to be reached. 26.01.2026 Jerry Canny FCCA, CPA Canny & Assoclates Chartèr8d C8rtlfl8d Accountants 60 Cannon Street London EC4N 6NP Date
LUNG CANCER RESEARCH (CHARITY COMMISSION NO. 11018231 BALANCE SHEET AS AT 31 DECEMBER 2024 UNRESTRICTED FUNDS UNRESTRICTED FUNDS 31 Decomber 2024 31 December 2023 Note Current assets HSBC Bank PIC 340,966 370,100 Total cash funits ,966 370,100 CTeditoTr within one year Accountancy charges Independent Examination charges 4.200 900 4,080 4,080 Net assets 335,866 366,020 Funds of the Charity Cash funds brought frirward, 31 December 2023 Net receiptsllpaymentsl durin9 the year 366.020 130,1541 471,656 {10o,6361 Totsl funds 335,866 366,020 Signed bylheTrusleeson.......................................................... Robin Ellison Alastair Meek (L'o Fkrrt)oigsr) fv IkLTrL6Tth Michael Seckl Nicci Wyborn
LUNG CANCER RESEARCH (CHARITY COMMISSION NO. 11018231 STATEMENT OF FINANCIAL ACTIVMES ISOFAI FOR THE YEAR ENDED 31 DECEMBER 2024 UNRESTRICTED FUNDS UNRESTRICTED FUNDS 31 December 2024 31 Dacembor 2023 Note Incoming resource$ Dorlon$ received 67,744 9.071 Total incoming re$ourc&s 67 744 Resources expended Accountancy charges Independent Examination charges Bank charges Imperial College for funding for lung cancer research Administration Expenses Registralion with the Fundraising Regulator 2,100 900 116 94,496 2.100 133 111.507 917 50 Total resources expended 97,898 114,707 Net movement In funds 130,154} 11a5,6361 Total funds brought fonvard. 31 December 2023 366,020 471.656 Total funds as at 31 December 2024 35, 366,020
LUNG CANCER RESEARCH {CHARITY COMMISSION NO. 1101823) NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 DECEMBER 2024 AccounUng policies Provision is included for all known current liabilities. Corrtingenl and future liabilrties are not included, expt where mentioned below by narrative note. Assets are shown at their value at the balance sheet d81e. Income Tax IITI. Capltal Galns Tax {CGTI and Inherhance Tax IIHTI The trust, as a charlty, is èxempl from IT and CGT on its investment income and ¢aprfEal gains. None of the restrictions on this relief, imposed by lax legislation, apply for this year. The trust is also exempt from IHT while ils funds ntinUe lo be held or applied for charitable purposes. 3 Donations The Trustees reiVed the following donations during this year.'- 2024 2023 Multiple payments Char((ies Trust Charl(able Giving Charities Aid Foundation Paypal Giving Fund Just Giving Memory Giving other 745 80 275 603 120 110 4.216 4,022 24,592 221 3,991 Singl& paym&nts Donatis 303 Legacies from 8slal8s Christine Bellamy 37,537 7,744 9,071 10